Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Gieryng, Anna ^a   Pszczolkowska, Dominika ^a   Bocian, Katarzyna ^a   Dabrowski, Michal ^a   Rajan, Wenson David ^a   Kloss, Michal ^a   Mieczkowski, Jakub ^a   Kaminska, Bozena ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BRAIN TUMOR; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNE EVASION; IMMUNOLOGY; MALE; METABOLISM; MICROGLIA; PATHOLOGY; RAT; SPECIES DIFFERENCE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; WISTAR RAT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; IMMUNE EVASION; MALE; MICROGLIA; RATS; RATS, WISTAR; SPECIES SPECIFICITY; TRANSCRIPTION, GENETIC; TUMOR MICROENVIRONMENT;

EID: 85038825403     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-17752-w     Document Type: Article

References (82)

1. Hambardzumyan, D., Gutmann, D. H. & Kettenmann, H. The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 19, 20-27 (2015).
2. Mantovani, A. & Allavena, P. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 212, 435-445 (2015).
3. Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R. & Kettenmann, H. The brain tumor microenvironment. Glia 59, 1169-1180 (2011).
4. Pitt, J. M. et al. Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. Annals of Oncology 27, 1482-1492 (2016).
5. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
6. Van Meir, E. G. et al. Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. CA. Cancer J. Clin. 60, 166-193 (2010).
7. Birk, H. S., Han, S. J. & Butowski, N. A. Treatment options for recurrent high-grade gliomas. CNS Oncol. 6, 61-70 (2016).
8. Gieryng, A. & Kaminska, B. Myeloid-derived suppressor cells in gliomas. Contemp. Oncol. Onkol. 20, 345-351 (2016).
9. Kaminska, B. In GliomaCell Biology(eds. Sedo, A. & Mentlein, R.)241-270 (Springer Vienna, 2014). https://doi. org/10. 1007/978-3-7091-1431-5-9
10. Mieczkowski, J. et al. Down-regulation of IKK? expression in glioma-infiltrating microglia/macrophages is associated with defective inflammatory/immune gene responses in glioblastoma. Oncotarget 6, 33077-90 (2015).
11. Chang, A. L. et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory t cells and myeloidderived suppressor cells. Cancer Res. 76, 5671-5682 (2016).
12. Dubinski, D. et al. CD4 + T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro. Oncol. 18, 807-818 (2016).
13. Iglesia, M. D. et al. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. J Natl Cancer Inst 108, (2016).
14. Gieryng, A., Pszczolkowska, D., Walentynowicz, K. A., Rajan, W. D. & Kaminska, B. Immune microenvironment of gliomas. Lab Invest (2017).
15. Hussain, S. F. et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro. Oncol. 8, 261-279 (2006).
16. Markovic, D. S. et al. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J. Neuropathol. Exp. Neurol. 64, 754-62 (2005).
17. Markovic, D. S. et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl. Acad. Sci. USA 106, 12530-5 (2009).
18. Sliwa, M. et al. The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A. Brain 130, 476-489 (2007).
19. Wesolowska, A. et al. Microglia-derived TGF-b as an important regulator of glioblastoma invasion-an inhibition of TGF-bdependent effects by shRNA against human TGF-b type II receptor. Oncogene 27, 918-930 (2008).
20. Fecci, P. E. et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66, 3294-3302 (2006).
21. Wainwright, D. A., Dey, M., Chang, A. & Lesniak, M. S. Targeting tregs in malignant brain cancer: Overcoming IDO. Frontiers in Immunology 4, (2013).
22. Murray, P. J. et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity 41, 14-20 (2014).
23. Szulzewsky, F. et al. Human glioblastoma-associated microglia/monocytes express a distinct RNA profile compared to human control and murine samples. Glia 64, 1416-1436 (2016).
24. Gabrusiewicz, K. et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI insight 1, 1-32 (2016).
25. Lohr, J. et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-Clin. Cancer Res. 17, 4296-4308 (2011).
26. Alexiou, G. A. et al. Circulating progenitor cells: a comparison of patients with glioblastoma or meningioma. Acta Neurol Belg 113, 7-11 (2013).
27. Hvarness, T. et al. Phenotypic characterisation of immune cell infiltrates in testicular germ cell neoplasia. J. Reprod. Immunol. 100, 135-145 (2013).
28. Hussain, S. F., Yang, D., Suki, D., Grimm, E. & Heimberger, A. B. Innate immune functions of microglia isolated from human glioma patients. J. Transl. Med. 4, 15 (2006).
29. Barth, R. F. & Kaur, B. Rat brain tumor models in experimental neuro-oncology: The C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. Journal of Neuro-Oncology 94, 299-312 (2009).
30. Doblas, S. et al. Glioma morphology and tumor-induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography. J. Magn. Reson. Imaging 32, 267-275 (2010).
31. Beißbarth, T. & Speed, T. P. GOstat: Find statistically overrepresented Gene Ontologies with a group of genes. Bioinformatics 20, 1464-1465 (2004).
32. Verhaak, R. G. W. et al. Article Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized. Cancer Cell 17, 98-110 (2010).
33. Sedgwick, J. D. et al. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc. Natl. Acad. Sci. USA 88, 7438-7442 (1991).
34. Sedgwick, J. D., Schwender, S., Gregersen, R., Dörries, R. & ter Meulen, V. Resident macrophages (ramified microglia) of the adult brown Norway rat central nervous system are constitutively major histocompatibility complex class II positive. J. Exp. Med. 177, 1145 LP-1152 (1993).
35. Günther, E. & Walter, L. The major histocompatibility complex of the rat (Rattus norvegicus). Immunogenetics 53, 520-542 (2001).
36. Malumbres, M. Cyclin-dependent kinases. Genome Biol. 15, 122 (2014).
37. Vagnarelli, P. et al. Repo-Man Coordinates Chromosomal Reorganization with Nuclear Envelope Reassembly during Mitotic Exit. Dev. Cell 21, 328-342 (2011).
38. Ellert-Miklaszewska, A. et al. Molecular definition of the pro-tumorigenic phenotype of glioma-activated microglia. Glia 61, 1178-1190 (2013).
39. Szulzewsky, F. et al. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One 10, (2015).
40. Carroll, H. P., Paunovi?, V. & Gadina, M. Signalling, inflammation and arthritis: Crossed signals: The role of interleukin-15 and-18 in autoimmunity. Rheumatology 47, 1269-1277 (2008).
41. Teng, M. W. L. et al. IL-12 and IL-23cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719-729 (2015).
42. Santini, S. M. et al. Interferon-conditioned human monocytes combine a TH1-orienting attitude with the induction of autologous TH17 responses: Role of IL-23 and IL-12. PLoS One 6, (2011).
43. Langrish, C. L. et al. IL-12 and IL-23: Master regulators of innate and adaptive immunity. Immunological Reviews 202, 96-105 (2004).
44. Keillor, J. W., Apperley, K. Y. P. & Akbar, A. Inhibitors of tissue transglutaminase. Trends in Pharmacological Sciences 36, 32-40 (2015).
45. Yoshie, O. & Matsushima, K. CCR4 and its ligands: From bench to bedside. Int. Immunol. 27, 11-20 (2015).
46. Deng, L., Chen, N., Li, Y., Zheng, H. & Lei, Q. CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Biochim. Biophys. Acta-Rev. Cancer 1806, 42-49 (2010).
47. Groom, J. R. & Luster, A. D. CXCR3 in T cell function. Experimental Cell Research 317, 620-631 (2011).
48. Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207-15 (2011).
49. Badie, B. & Schartner, J. M. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46, 957-962 (2000).
50. Gabrusiewicz, K. et al. Characteristics of the Alternative Phenotype of Microglia/Macrophages and its Modulation in Experimental Gliomas. PLoS One 6, 1-12 (2011).
51. Gabrusiewicz, K. et al. Macrophage Ablation Reduces M2-Like Populations and Jeopardizes Tumor Growth in a MAFIA-Based Glioma Model. Neoplasia 17, 374-384 (2015).
52. Müller, A., Brandenburg, S., Turkowski, K., Müller, S. & Vajkoczy, P. Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells. Int. J. Cancer 137, 278-288 (2015).
53. Parney, I. F., Waldron, J. S. & Parsa, A. T. Flow cytometry and in vitro analysis of human glioma-associated macrophages. J. Neurosurg. 110, 572-582 (2009).
54. De Sanctis, F. et al. MDSCs in cancer: Conceiving new prognostic and therapeutic targets. Biochim. Biophys. Acta-Rev. Cancer 1865, 35-48 (2016).
55. Arina, A. & Bronte, V. Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. Curr. Opin. Immunol. 33, 120-125 (2015).
56. Marvel, D. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Investig. 125, 3356-3364 (2015).
57. Raychaudhuri, B. et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J. Neurooncol. 122, 293-301 (2015).
58. Barnett, B., Kryczek, I., Cheng, P., Zou, W. & Curiel, T. J. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. 54, 369-77 (2005).
59. Chattopadhyay, S. et al. Effect of CD4 + CD25 + and CD4 + CD25T-Regulatory Cells on the Generation of Cytolytic T Cell Response to a Self but Human Tumor-Associated Epitope In Vitro. J. Immunol. 176, 984 LP-990 (2006).
60. Orozco-Morales, M. et al. Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin. J. Cancer Res. Clin. Oncol. 138, 23-33 (2012).
61. Savage, N. D. L. et al. Human Anti-Inflammatory Macrophages Induce Foxp3 + GITR + CD25 + Regulatory T Cells, Which Suppress via Membrane-Bound TGF?-1. J. Immunol. 181, 2220-2226 (2008).
62. Engler, J. R. et al. Increased Microglia/Macrophage Gene Expression in a Subset of Adult and Pediatric Astrocytomas. PLoS One 7, 1-12 (2012).
63. Hung, N. A. et al. Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma. Mod Pathol 29, 212-226 (2016).
64. Bordey, A. & Sontheimer, H. Modulation of Glutamatergic Transmission by Bergmann Glial Cells in Rat Cerebellum In Situ. J. Neurophysiol. 89, 979 LP-988 (2003).
65. de Groot, J. & Sontheimer, H. Glutamate and the biology of gliomas. Glia 59, 1181-1189 (2011).
66. D'Angiolella, V., Esencay, M. & Pagano, M. A cyclin without cyclin-dependent kinases: Cyclin F controls genome stability through ubiquitin-mediated proteolysis. Trends in Cell Biology 23, 135-140 (2013).
67. Lee, B. et al. High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma. Gut Liver 8, 662-668 (2014).
68. Putluri, N. et al. Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance. Neoplasia 16, 390-402 (2014).
69. Ma, H. et al. Transcriptome analysis of glioma cells for the dynamic response to ?-irradiation and dual regulation of apoptosis genes: a new insight into radiotherapy for glioblastomas. Cell Death Dis. 4, e895 (2013).
70. Wordeman, L. How Kinesin Motor Proteins Drive Mitotic Spindle Function: Lessons from Molecular Assays. Semin. Cell Dev. Biol. 21, 260-268 (2010).
71. Rath, O. & Kozielski, F. Kinesins and cancer. Nat Rev Cancer 12, 527-539 (2012).
72. Machado-Neto, J. A. et al. Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. Leuk. Res. 38, 251-257 (2014).
73. Wang, R. et al. LRRC4 inhibits the proliferation of human glioma cells by modulating the expression of STMN1 and microtubule polymerization. J. Cell. Biochem. 112, 3621-3629 (2011).
74. Di Stefano, L., Jensen, M. R. & Helin, K. E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes. EMBO J. 22, 6289-6298 (2003).
75. Logan, N. et al. E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7. Oncogene 24, 5000-5004 (2005).
76. Li, J. et al. Synergistic Function of E2F7 and E2F8 is Essential for Cell Survival and Embryonic Development. Dev. Cell 14, 62-75 (2008).
77. Westendorp, B. et al. E2F7 represses a network of oscillating cell cycle genes to control S-phase progression. Nucleic Acids Res. 40, 3511-3523 (2012).
78. Weijts, B. G. M. W. et al. E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1. EMBO J. 31, 3871-3884 (2012).
79. Brandenburg, S. et al. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors. Acta Neuropathol. 131, 365-378 (2016).
80. Patel, D. et al. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Hum. Gene Ther. Clin. Dev. https://doi. org/10. 1089/hum. 2016. 031 (2016).
81. Mathios, D. et al. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int. J. Cancer 138, 187-194 (2016).
82. Jordan, J. T. et al. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol. Immunother. 57, 123-131 (2008).